This is an investigation of the safety, tolerance and efficacious dosage of ganciclovir for administration to infants with congenital CMV disease in Phase I and Phase II trials, and Phase III trial now is enrolling and following subjects to determine impact of treatment on death, growth, neurodevelopment, hearing loss and vision loss.
Showing the most recent 10 out of 459 publications